Is Novo Nordisk (NVO) a Buy Right Now?
A plain-English read on Novo Nordisk stock — what the chart and the numbers are saying today, with no jargon and no hype.
What this means, in plain English
Novo Nordisk is trading at $44.88, down 0.95% today. The stock is currently below its 200-day average of $46.44, which is a common measure used to identify a long-term downward trend. When a price sits below this line, it often signals that momentum is currently working against the stock.
The RSI, or Relative Strength Index—a gauge of whether a stock has climbed too far or fallen too fast—sits at 38.8. This suggests the stock is not yet extremely oversold, but it remains in a weak position. With the price hovering near its $43.68 floor, or support level, caution is warranted.
Should you buy Novo Nordisk stock?
Deciding to buy depends on your risk tolerance, but the current downward trend makes this a time to be very careful. With the price struggling to stay above its long-term averages, there is no clear signal that the stock has found its footing yet.
Is NVO a good stock for beginners?
Novo Nordisk is a large company, but its current price behavior shows significant volatility, or rapid and unpredictable price swings. A beginner should be cautious because the stock is currently trading well below its 52-week high of $64.16.
What's driving NVO right now
The stock is currently trading below its 200-day average of $46.44.
The price is approaching a recent floor of $43.68.
The RSI of 38.8 indicates the stock is currently lacking upward strength.
A P/E ratio of 2.1 might suggest the stock is priced low relative to its earnings.
What Novo Nordisk actually does
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Who owns Novo Nordisk?
Institutions — pension funds, asset managers, index providers — hold 9.9% of NVO, and the concentration matters: the largest single holder alone controls 0.60% of the company.
| Holder | Shares | % held |
|---|---|---|
| 20.40M | 0.60% | |
| 17.02M | 0.50% | |
| 13.04M | 0.38% |
Names withheld — plus 3 more records not shown.
See who owns itThe numbers behind the read
Who in Washington has been trading NVO?
Members of Congress must disclose trades over $1,000 within 45 days under the STOCK Act. 14 disclosures name NVO — filed by 6 separate members and worth $56K–$315K combined (filings report bands, never exact amounts). 10 purchase-side, 4 sale-side, most recently on 2025-10-15.
| Member | Date | Action | Amount filed |
|---|---|---|---|
| 2025-10-15 | BUY | $1,001 - $15,000 | |
| 2025-08-28 | BUY | $1,001 - $15,000 | |
| 2025-08-19 | BUY | $15,001 - $50,000 |
Names withheld — plus 11 more records not shown.
See which membersThe stock is currently in a downward trend and sitting near its floor, so it is best to remain careful and observe.
Don't guess. Practice this trade first.
Buy it with virtual cash and watch how it plays out — before a dollar of your own is on the line.
Practice NVO risk-free in your paper portfolioPaper trading, the AI Read & live indicators are inside a Money GPS membership — one price, the whole platform.
Beginner questions about NVO
Should I buy NVO stock?+
With the stock trending downward and priced at $44.88, it is wise to be careful before making any decisions.
Is NVO a good long-term investment?+
The stock is currently below its 200-day average of $46.44, which indicates a challenging environment for long-term holders right now.
Is NVO a buy or a sell?+
The current downward trend and an RSI of 38.8 suggest a cautious approach rather than an immediate buy.
Is NVO overvalued?+
With a P/E ratio of 2.1, the stock is priced low relative to its earnings, though it remains in a downward trend.
Is NVO a good stock for beginners?+
Beginners should be careful as the stock has moved between $35.12 and $64.16 over the past year, showing significant volatility.
Important disclaimer
This page is for educational and informational purposes only and is not financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy, sell, or hold Novo Nordisk (NVO) or any other security. The Money GPS is not a registered investment adviser, broker-dealer, or financial planner, and no content here should be relied upon to make an investment decision.
The verdict, indicators, and commentary are generated automatically — in part using AI — from third-party market data (via Yahoo Finance) that may be delayed, incomplete, or inaccurate, and is provided “as is” without any warranty. Figures reflect the market as of 2026-08-17 and change constantly; the read above may already be out of date. A “Buy,” “Hold,” or “Be Careful” label is a simplified, rules-based signal for beginners — not a price target or a guarantee of any outcome.
All investing involves risk, including the possible loss of your entire principal. Past performance and historical patterns do not guarantee future results. Always do your own research and consult a licensed financial professional who knows your personal circumstances before investing. You are solely responsible for your own investment decisions. The Money GPS and its authors may hold positions in the securities discussed and accept no liability for any loss arising from the use of this information.